60 Degrees Pharmaceuticals Announces 65% YoY Revenue Growth, Exhausts Shelf Capacity

60 Degrees Pharmaceuticals reported FY 2025 net product revenues of $1,005,000, a 65% increase from $607.6 thousand in 2024. Operating expenses were $8.4 million, compared to $10.0 million in 2024. The company achieved a gross profit of approximately $223.8 thousand and a net loss of $7.37 million, or $11.73 per share. Recent business highlights include exhausting current shelf capacity after raising $4 million through an ATM facility and partnering with GoodRx to provide discounts on ARAKODA.